Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.
NCT ID: NCT00287534
Last Updated: 2009-06-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
1059 participants
INTERVENTIONAL
1996-11-30
2004-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years
NCT00286117
ATAC - Arimidex, Tamoxifen Alone or in Combination
NCT00849030
PROACT - Pre-Operative Arimidex Compared To Tamoxifen
NCT00232661
ATAC - Endometrial Sub-Protocol
NCT00814125
Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients
NCT00309491
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Anastrozole
Anastrozole
oral
2
Tamoxifen
Tamoxifen
oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anastrozole
oral
Tamoxifen
oral
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Post-menopausal women ≤75 years,
* histologically confirmed invasive breast carcinoma (no distant metastases),
* positive hormone receptor status,
* continuous 2-year adjuvant tamoxifen therapy 20 mg/30 mg with 4 weeks after primary surgery
Exclusion Criteria
* pre-operative chemotherapy or hormone therapy or radiation therapy,
* relapse or second carcinoma or previous cancerous disease,
* breast carcinoma in situ,
* simultaneous carcinoma of the opposite side or secondary breast,
* 10 or more tumour-infiltrated lymph nodes.
* serious accompanying diseases
75 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
German Adjuvant Breast Cancer Group
OTHER
AstraZeneca
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Manfred Kaufmann, MD
Role: PRINCIPAL_INVESTIGATOR
German Adjuvant Breast Cancer Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Albstadt, , Germany
Research Site
Berlin, , Germany
Research Site
Cloppenburg, , Germany
Research Site
Eggenfelden, , Germany
Research Site
Frankfurt, , Germany
Research Site
Freiburg im Breisgau, , Germany
Research Site
Göttingen, , Germany
Research Site
Halle, , Germany
Research Site
Hamburg, , Germany
Research Site
Hanau, , Germany
Research Site
Hanover, , Germany
Research Site
Heidelberg, , Germany
Research Site
Hoyerswerda, , Germany
Research Site
Idar-Oberstein, , Germany
Research Site
Jena, , Germany
Research Site
Karlsruhe, , Germany
Research Site
Kassel, , Germany
Research Site
Kiel, , Germany
Research Site
Leonberg, , Germany
Research Site
Lingen, , Germany
Research Site
Lübeck, , Germany
Research Site
Magdeburg, , Germany
Research Site
Mainz, , Germany
Research Site
Mannheim, , Germany
Research Site
München, , Germany
Research Site
Münster, , Germany
Research Site
Neustadt, , Germany
Research Site
Osnabrück, , Germany
Research Site
Paderborn, , Germany
Research Site
Pforzheim, , Germany
Research Site
Recklinghausen, , Germany
Research Site
Rosenheim, , Germany
Research Site
Rostock, , Germany
Research Site
Rüsselsheim am Main, , Germany
Research Site
Schleswig, , Germany
Research Site
Siegen, , Germany
Research Site
Titisee-Neustadt, , Germany
Research Site
Tübingen, , Germany
Research Site
Ulm, , Germany
Research Site
Waiblingen, , Germany
Research Site
Westerstede, , Germany
Research Site
Worms, , Germany
Research Site
Würzburg, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ARNO-95
Identifier Type: -
Identifier Source: secondary_id
1033GR/0001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.